A general strategy to construct small molecule biosensors in eukaryotes

  1. Justin Feng
  2. Benjamin W Jester
  3. Christine E Tinberg
  4. Daniel J Mandell  Is a corresponding author
  5. Mauricio S Antunes
  6. Raj Chari
  7. Kevin J Morey
  8. Xavier Rios
  9. June I Medford
  10. George M Church
  11. Stanley Fields
  12. David Baker
  1. Harvard Medical School, United States
  2. University of Washington, United States
  3. Colorado State University, United States
  4. Howard Hughes Medical Institute, University of Washington, United States

Abstract

Biosensors for small molecules can be used in applications that range from metabolic engineering to orthogonal control of transcription. Here, we produce biosensors based on a ligand-binding domain (LBD) by using a method that, in principle, can be applied to any target molecule. The LBD is fused to either a fluorescent protein or a transcriptional activator and is destabilized by mutation such that the fusion accumulates only in cells containing the target ligand. We illustrate the power of this method by developing biosensors for digoxin and progesterone. Addition of ligand to yeast, mammalian or plant cells expressing a biosensor activates transcription with a dynamic range of up to ~100-fold. We use the biosensors to improve the biotransformation of pregnenolone to progesterone in yeast and to regulate CRISPR activity in mammalian cells. This work provides a general methodology to develop biosensors for a broad range of molecules in eukaryotes.

Article and author information

Author details

  1. Justin Feng

    Program in Biological and Biomedical Sciences, Harvard Medical School, Boston, United States
    Competing interests
    Justin Feng, has filed a provisional application (patent application number 62220628) with the US Patent and Trademark Office on this work.
  2. Benjamin W Jester

    Department of Genome Sciences, University of Washington, Seattle, United States
    Competing interests
    Benjamin W Jester, has filed a provisional application (patent application number 62220628) with the US Patent and Trademark Office on this work.
  3. Christine E Tinberg

    Department of Biochemistry, University of Washington, Seattle, United States
    Competing interests
    Christine E Tinberg, has filed a provisional application (patent application number 62220628) with the US Patent and Trademark Office on this work.
  4. Daniel J Mandell

    Department of Genetics, Harvard Medical School, Boston, United States
    For correspondence
    djmandell@gmail.com
    Competing interests
    Daniel J Mandell, has filed a provisional application (patent application number 62220628) with the US Patent and Trademark Office on this work. Harvard University has filed a provisional patent.
  5. Mauricio S Antunes

    Department of Biology, Colorado State University, Fort Collins, United States
    Competing interests
    No competing interests declared.
  6. Raj Chari

    Department of Genetics, Harvard Medical School, Boston, United States
    Competing interests
    Raj Chari, has filed a provisional application (patent application number 62220628) with the US Patent and Trademark Office on this work.
  7. Kevin J Morey

    Department of Biology, Colorado State University, Fort Collins, United States
    Competing interests
    No competing interests declared.
  8. Xavier Rios

    Department of Genetics, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  9. June I Medford

    Department of Biology, Colorado State University, Fort Collins, United States
    Competing interests
    No competing interests declared.
  10. George M Church

    Department of Genetics, Harvard Medical School, Boston, United States
    Competing interests
    George M Church, has filed a provisional application (patent application number 62220628) with the US Patent and Trademark Office on this work.
  11. Stanley Fields

    Department of Genome Sciences, University of Washington, Seattle, United States
    Competing interests
    Stanley Fields, has filed a provisional application (patent application number 62220628) with the US Patent and Trademark Office on this work.
  12. David Baker

    Howard Hughes Medical Institute, University of Washington, Seattle, United States
    Competing interests
    David Baker, has filed a provisional application (patent application number 62220628) with the US Patent and Trademark Office on this work.

Copyright

© 2015, Feng et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 14,039
    views
  • 3,226
    downloads
  • 139
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Justin Feng
  2. Benjamin W Jester
  3. Christine E Tinberg
  4. Daniel J Mandell
  5. Mauricio S Antunes
  6. Raj Chari
  7. Kevin J Morey
  8. Xavier Rios
  9. June I Medford
  10. George M Church
  11. Stanley Fields
  12. David Baker
(2015)
A general strategy to construct small molecule biosensors in eukaryotes
eLife 4:e10606.
https://doi.org/10.7554/eLife.10606

Share this article

https://doi.org/10.7554/eLife.10606

Further reading

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Katherine A Senn, Karli A Lipinski ... Aaron A Hoskins
    Research Article

    Pre-mRNA splicing is catalyzed in two steps: 5ʹ splice site (SS) cleavage and exon ligation. A number of proteins transiently associate with spliceosomes to specifically impact these steps (first and second step factors). We recently identified Fyv6 (FAM192A in humans) as a second step factor in Saccharomyces cerevisiae; however, we did not determine how widespread Fyv6’s impact is on the transcriptome. To answer this question, we have used RNA sequencing (RNA-seq) to analyze changes in splicing. These results show that loss of Fyv6 results in activation of non-consensus, branch point (BP) proximal 3ʹ SS transcriptome-wide. To identify the molecular basis of these observations, we determined a high-resolution cryo-electron microscopy (cryo-EM) structure of a yeast product complex spliceosome containing Fyv6 at 2.3 Å. The structure reveals that Fyv6 is the only second step factor that contacts the Prp22 ATPase and that Fyv6 binding is mutually exclusive with that of the first step factor Yju2. We then use this structure to dissect Fyv6 functional domains and interpret results of a genetic screen for fyv6Δ suppressor mutations. The combined transcriptomic, structural, and genetic studies allow us to propose a model in which Yju2/Fyv6 exchange facilitates exon ligation and Fyv6 promotes usage of consensus, BP distal 3ʹ SS.

    1. Biochemistry and Chemical Biology
    2. Neuroscience
    Eyal Paz, Sahil Jain ... Abdussalam Azem
    Research Article

    TIMM50, an essential TIM23 complex subunit, is suggested to facilitate the import of ~60% of the mitochondrial proteome. In this study, we characterized a TIMM50 disease-causing mutation in human fibroblasts and noted significant decreases in TIM23 core protein levels (TIMM50, TIMM17A/B, and TIMM23). Strikingly, TIMM50 deficiency had no impact on the steady-state levels of most of its putative substrates, suggesting that even low levels of a functional TIM23 complex are sufficient to maintain the majority of TIM23 complex-dependent mitochondrial proteome. As TIMM50 mutations have been linked to severe neurological phenotypes, we aimed to characterize TIMM50 defects in manipulated mammalian neurons. TIMM50 knockdown in mouse neurons had a minor effect on the steady state level of most of the mitochondrial proteome, supporting the results observed in patient fibroblasts. Amongst the few affected TIM23 substrates, a decrease in the steady state level of components of the intricate oxidative phosphorylation and mitochondrial ribosome complexes was evident. This led to declined respiration rates in fibroblasts and neurons, reduced cellular ATP levels, and defective mitochondrial trafficking in neuronal processes, possibly contributing to the developmental defects observed in patients with TIMM50 disease. Finally, increased electrical activity was observed in TIMM50 deficient mice neuronal cells, which correlated with reduced levels of KCNJ10 and KCNA2 plasma membrane potassium channels, likely underlying the patients’ epileptic phenotype.